Evidence map›Paper›PMID 34791587›Full record

ArticleJournal of clinical immunology2022

CARD9 Expression Pattern, Gene Dosage, and Immunodeficiency Phenotype Revisited.

Shubham Goel, Hye Sun Kuehn, Javier Chinen, Julie Niemela, Jennifer Stoddard, Daisuke Yamanaka, Mary Garofalo, Sophia Samir, Melanie Migaud, Vasileios Oikonomou and 4 more

Open access · greenAbstract read
In one paragraph

Article in Journal of clinical immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Probable invasiveIDCases · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. CARD9 Signaling, Inflammation, and Diseases.Frontiers in immunology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Shubham Goel *Immunology Service, Department of Laboratory Medicine, Clinical Center, NIH, MD, Bethesda, USA.
Hye Sun Kuehn *Immunology Service, Department of Laboratory Medicine, Clinical Center, NIH, MD, Bethesda, USA.
Javier ChinenImmunology, Allergy and Rheumatology Division, Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA.
Julie NiemelaImmunology Service, Department of Laboratory Medicine, Clinical Center, NIH, MD, Bethesda, USA.
Jennifer StoddardImmunology Service, Department of Laboratory Medicine, Clinical Center, NIH, MD, Bethesda, USA.
Daisuke YamanakaLaboratory of Clinical Immunology and Microbiology, Fungal Pathogenesis Section, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, USA.
Mary GarofaloImmunology Service, Department of Laboratory Medicine, Clinical Center, NIH, MD, Bethesda, USA.
Sophia SamirImmunology Service, Department of Laboratory Medicine, Clinical Center, NIH, MD, Bethesda, USA.
Melanie MigaudLaboratory of Human Genetics of Infectious Diseases, Necker Branch, UMR 1163, INSERM, Necker Hospital for Sick Children, 75015, Paris, France.
Vasileios OikonomouLaboratory of Clinical Immunology and Microbiology, Fungal Pathogenesis Section, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, USA.
Thomas FleisherImmunology Service, Department of Laboratory Medicine, Clinical Center, NIH, MD, Bethesda, USA.
Anne PuelLaboratory of Human Genetics of Infectious Diseases, Necker Branch, UMR 1163, INSERM, Necker Hospital for Sick Children, 75015, Paris, France.
Michail S LionakisLaboratory of Clinical Immunology and Microbiology, Fungal Pathogenesis Section, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, USA.
Sergio D RosenzweigImmunology Service, Department of Laboratory Medicine, Clinical Center, NIH, MD, Bethesda, USA. srosenzweig@cc.nih.gov.
National Institutes of Health Clinical Center · USNational Institute of Allergy and Infectious Diseases · USUniversité Paris Cité · FRTexas Children's Hospital · US

Funding

Immunopathogenesis of Fungal InfectionsZIAAI001175 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI LIONAKIS, MICHAIL · 2012 to 2025
$23.9M
Genome-wide search for inborn errors of IL-17 immunity underlying chronic mucocutaneous candidiasisR01AI127564 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI Jean-Laurent Casanova, Anne Puel · 2017 to 2026
$4.8M
Intramural NIH HHS Z99 CL999999NIAID NIH HHS R01 AI127564
6 · The paper itself

Abstract

backgroundCARD9 deficiency is an autosomal recessive primary immunodeficiency underlying increased susceptibility to fungal infection primarily presenting as invasive CNS Candida and/or cutaneous/invasive dermatophyte infections. More recently, a rare heterozygous dominant negative CARD9 variant c.1434 + 1G > C was reported to be protective from inflammatory bowel disease.

objectiveWe studied two siblings carrying homozygous CARD9 variants (c.1434 + 1G > C) and born to heterozygous asymptomatic parents. One sibling was asymptomatic and the other presented with candida esophagitis, upper respiratory infections, hypogammaglobulinemia, and low class-switched memory B cells. METHODS AND

resultsThe CARD9 c.1434 + 1G > C variant generated two mutant transcripts confirmed by mRNA and protein expression: an out-of-frame c.1358-1434 deletion/ ~ 55 kDa protein (CARD9Δex.11) and an in-frame c.1417-1434 deletion/ ~ 61 kDa protein (CARD9Δ18 nt.). Neither transcript was able to form a complete/functional CBM complex, which includes TRIM62. Based on the index patient's CVID-like phenotype, CARD9 expression was tested and detected in lymphocytes and monocytes from humans and mice. The functional impact of different CARD9 mutations and gene dosage conditions was evaluated in heterozygous and homozygous c.1434 + 1 G > C members of the index family, and in WT (two WT alleles), haploinsufficiency (one WT, one null allele), and null (two null alleles) individuals. CARD9 gene dosage impacted lymphocyte and monocyte functions including cytokine generation, MAPK activation, T-helper commitment, transcription, plasmablast differentiation, and immunoglobulin production in a differential manner.

conclusionsCARD9 exon 11 integrity is critical to CBM complex function. CARD9 is expressed and affects particular T and B cell functions in a gene dosage-dependent manner, which in turn may contribute to the phenotype of CARD9 deficiency.

Indexed as

Candidiasis, Chronic MucocutaneousAllelesAnimalsCARD Signaling Adaptor ProteinsGene DosageHomozygoteHumansMicePhenotypeCARD9 protein, humanCard9 protein, mouseCARD Signaling Adaptor ProteinsB cells, Th17BCL10CandidaCARD9CBM complexfungal infectionhuman immunologyinflammatory bowel diseaseMALT1MAPK signalingmouse immunologyT cellsTRIM62

Identifiers

PMID34791587
PMCPMC10108093
OpenAlexW3214169322

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.